FBL and metabolic dysfunction-associated steatohepatitis: Complementarily, the differentially enriched pathways within the comparisons between PF vs. PLI and between Fib vs. Lob are consistent with fibrosis being the widely recognized hallmark of disease progression in NASH (Figure 3C and Figure S1C).